Head & neck cancer patients 1 tab tid for at least 12 wk. Usual dose range: 3-6 tab/day (not to exceed 2 tab/dose). Sjogren's syndrome patient 1 tab qid for at least 6 wk.
CV disease; controlled asthma, chronic bronchitis or COPD. Known or suspected cholelithiasis or biliary tract disease; nephrolithiasis; underlying cognitive or psychiatric disturbances; hepatic insufficiency. May affect ability to drive or operate machinery. Childn. Pregnancy & lactation.
May cause conduct disturbances w/ β-adrenergic antagonists. Additive pharmacologic effects w/ parasympathomimetic drugs. Anticholinergic effects of drugs may be antagonized.